Page last updated: 2024-12-07

desethylamodiaquine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

desethylamodiaquine: metabolite of amodiaquine [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID122068
CHEMBL ID1235
SCHEMBL ID14067597
MeSH IDM0136880

Synonyms (34)

Synonym
4-((7-chloro-4-quinolinyl)amino)-2-((ethylamino)methyl)phenol
n-desethylamodiaquine
desethylamodiaquine
monodesethylamodiaquine
79352-78-6
n-monodesethylamodiaquine (deaq)
CHEMBL1235 ,
FT-0665940
bdbm50056190
4-(7-chloro-quinolin-4-ylamino)-2-ethylaminomethyl-phenol
bidesethylamodiaquine
desethyl amodiaquine
4-[(7-chloroquinolin-4-yl)amino]-2-(ethylaminomethyl)phenol
4-[(7-chloro-4-quinolyl)amino]-2-(ethylaminomethyl)phenol
by36sg7np9 ,
unii-by36sg7np9
phenol, 4-((7-chloro-4-quinolinyl)amino)-2-((ethylamino)methyl)-
DTXSID20229630
SCHEMBL14067597
n-desethyl amodiaquine
n-desethyl amodiaquine-d5?phenol,2-(aminomethyl)-4-[(7-chloro-4-quinolinyl)amino]-
AC-27753
AKOS025401980
2-(aminomethyl)-4-[(7-chloro-4-quinolinyl)amino]phenol
4-((7-chloroquinolin-4-yl)amino)-2-((ethylamino)methyl)phenol
HY-128554
BCP34368
SB73009
CS-0095816
F82403
MS-24901
4-((7-chloranylquinolin-4-yl)amino)-2-(ethylaminomethyl)phenol
A933931
(discontinued see d288826)

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" After both 2 h and 16 h incubations CQ was the least toxic and AQQI the most toxic of the four compounds towards MNL."( The toxicity of amodiaquine and its principal metabolites towards mononuclear leucocytes and granulocyte/monocyte colony forming units.
Breckenridge, AM; Coleman, JW; Maggs, JL; Park, BK; Winstanley, PA, 1990
)
0.28
" After a 48-h treatment, ADQ and NADQ caused cytotoxicity and induced apoptosis in HepG2 cells; NADQ was slightly more toxic than ADQ."( Apoptosis contributes to the cytotoxicity induced by amodiaquine and its major metabolite N-desethylamodiaquine in hepatic cells.
Beland, FA; Chen, S; Fang, JL; Tang, Y; Wu, Q, 2020
)
0.78

Pharmacokinetics

24 pregnant women in the second and third trimesters of pregnancy and with Plasmodium vivax malaria were treated with amodiaquine (10 mg/kg of body weight/day) for 3 days. The exposure and half-life of desethylamodiaqine increased by approximately 11% and 21%, respectively, with concurrent administration.

ExcerptReferenceRelevance
" In an attempt to explain the discrepancy between its in vivo-in vitro activity, a pharmacokinetic study was conducted in healthy subjects with HPLC assays."( [Pharmacokinetics of amodiaquine and prevention of Plasmodium falciparum malaria].
Blayo, MC; Faurisson, F; Pussard, E; Verdier, F, 1985
)
0.27
" Blood samples from children in two studies in Zanzibar and one in Papua New Guinea were included in the pharmacokinetic analysis (n = 86)."( Population pharmacokinetics of amodiaquine and desethylamodiaquine in pediatric patients with uncomplicated falciparum malaria.
Ali, AS; Ashton, M; Bhattarai, A; Björkman, A; Hietala, SF; Hombhanje, FW; Kaneko, A; Msellem, M; Röshammar, D; Strömberg, J, 2007
)
0.6
" The main disposition parameters to AS+AQ were: for DHA, AUC = 632 +/- 475 ng h/ml and Cmax = 432 +/- 325 ng/ml, and for MdAQ = 14268 +/- 4114 ng h/ml and Cmax = 336 +/- 225 ng/ml (mean +/- standard deviation)."( Pharmacokinetics and pharmacodynamics of a new ACT formulation: Artesunate/Amodiaquine (TRIMALACT) following oral administration in African malaria patients.
Alegre, SS; Benakis, A; Bertaux, L; Lwango, R; Malaika, LT; Parzy, D; Sinou, V; Sugnaux, F; Taudon, N,
)
0.13
"In order to study the pharmacokinetic properties of amodiaquine and desethylamodiaquine during pregnancy, 24 pregnant women in the second and third trimesters of pregnancy and with Plasmodium vivax malaria were treated with amodiaquine (10 mg/kg of body weight/day) for 3 days."( Pharmacokinetics of amodiaquine and desethylamodiaquine in pregnant and postpartum women with Plasmodium vivax malaria.
Cammas, M; Hsi, P; Jullien, V; Lindegardh, N; McGready, R; Nosten, F; Phyo, AP; Rijken, MJ; Singhasivanon, P; Tarning, J; White, NJ; Win, AK, 2011
)
0.88
"Amodiaquine is effective for the treatment of Plasmodium vivax malaria, but there is little information on the pharmacokinetic and pharmacodynamic properties of amodiaquine in pregnant women with malaria."( Population pharmacokinetic and pharmacodynamic modeling of amodiaquine and desethylamodiaquine in women with Plasmodium vivax malaria during and after pregnancy.
Bergstrand, M; Cammas, M; Chotsiri, P; Day, NP; Jullien, V; Lindegardh, N; McGready, R; Nosten, F; Rijken, MJ; Singhasivanon, P; Tarning, J; White, NJ, 2012
)
0.61
"The study established pharmacokinetic interaction between AQ and MO when given together or following a long period of ingestion of MO."( Moringa oleifera leaf powder alters the pharmacokinetics of amodiaquine in healthy human volunteers.
Adeagbo, BA; Bolaji, OO; Olawoye, OS, 2018
)
0.48
" The present study hence evaluated the effect of MD on the disposition of AQ in mice with a view to investigating a possible pharmacokinetic interaction."( Influence of MAMA decoction, an Herbal Antimalarial, on the Pharmacokinetics of Amodiaquine in Mice.
Adeagbo, BA; Adehin, A; Adepiti, AO; Bolaji, OO; Elujoba, AA, 2020
)
0.56
" The exposure and half-life of desethylamodiaquine increased by approximately 11% and 21%, respectively, with concurrent administration."( Influence of MAMA decoction, an Herbal Antimalarial, on the Pharmacokinetics of Amodiaquine in Mice.
Adeagbo, BA; Adehin, A; Adepiti, AO; Bolaji, OO; Elujoba, AA, 2020
)
0.84
" The increase in the half-life and systemic exposure of AQ following its co-administration with MD may provide a basis for the enhanced pharmacological effect of the combination in an earlier study in Plasmodium-infected mice."( Influence of MAMA decoction, an Herbal Antimalarial, on the Pharmacokinetics of Amodiaquine in Mice.
Adeagbo, BA; Adehin, A; Adepiti, AO; Bolaji, OO; Elujoba, AA, 2020
)
0.56
" Here, we evaluated the population pharmacokinetic properties of amodiaquine and its active metabolite, desethylamodiaquine, in children receiving SMC under directly observed ideal conditions (n = 136), and the adherence of SMC at an implementation phase in children participating in a case-control study to evaluate SMC effectiveness (n = 869)."( Adherence and Population Pharmacokinetic Properties of Amodiaquine When Used for Seasonal Malaria Chemoprevention in African Children.
Assao, B; Blessborn, D; Coldiron, ME; Ding, J; Grais, RF; Guindo, O; Koscalova, A; Langendorf, C; Tarning, J; Winterberg, M, 2020
)
0.77

Compound-Compound Interactions

ExcerptReferenceRelevance
"The effect of 16 alpha-acetoxy-26-hydroxycholest-4-ene-3,22-dione (SN-1) isolated from Solanum nudum Dunal (a Solanaceae traditionally used for treating fever in Colombia) on Plasmodium falciparum erythrocyte stages and its in vitro antiplasmodial activity when combined with the following conventional drugs was studied: chloroquine (CQ), amodiaquine (AQ), desethylamodiaquine (desethyl-AQ), quinine (QN), artemisinin (AR), atovaquone (ATV) and quinine (QN)."( Plasmodium falciparum: Solanum nudum SN-1 steroid antiplasmodial activity when combined with antimalarial drugs.
Blair, S; Deharo, E; Pabón, A, 2011
)
0.54

Bioavailability

ExcerptReferenceRelevance
" The method is sensitive, selective, accurate, reproducible and suited particularly for pharmacokinetic study of AS-AQ drug combination and can also be used to compare the bioavailability of different formulations, including a fixed-dose AS-AQ co-formulation."( Validation of high performance liquid chromatography-electrochemical detection methods with simultaneous extraction procedure for the determination of artesunate, dihydroartemisinin, amodiaquine and desethylamodiaquine in human plasma for application in c
Lai, CS; Mansor, SM; Muniandy, A; Nair, NK; Navaratnam, V; Olliaro, PL, 2009
)
0.54
"The aim of the present study was to compare the pharmacokinetic properties, bioavailability and tolerability of artesunate (AS) and amodiaquine (AQ) administered as a fixed-dose combination (Amonate FDC tablets; Dafra Pharma, Turnhout, Belgium) or as a non-fixed dose combination of separate AS tablets (Arsuamoon; Guilin Pharmaceutical Co, Shanghai, China) and AQ tablets (Flavoquine; Sanofi-Aventis, Paris, France)."( Comparative oral bioavailability of non-fixed and fixed combinations of artesunate and amodiaquine in healthy Indian male volunteers.
Fortin, A; Jansen, FH; Verbeeck, RK, 2011
)
0.37

Dosage Studied

ExcerptRelevanceReference
" The age-based dosing schedule currently recommended in Zanzibar appeared to result in inadequate exposure to N-DEAQ in many patients."( Population pharmacokinetics of amodiaquine and desethylamodiaquine in pediatric patients with uncomplicated falciparum malaria.
Ali, AS; Ashton, M; Bhattarai, A; Björkman, A; Hietala, SF; Hombhanje, FW; Kaneko, A; Msellem, M; Röshammar, D; Strömberg, J, 2007
)
0.6
" The nonlinear clearance of DEAQ and the wide variability in kinetic parameters have safety implications for weight-based dosing of higher-body-weight children with AQ."( Effect of concomitant artesunate administration and cytochrome P4502C8 polymorphisms on the pharmacokinetics of amodiaquine in Ghanaian children with uncomplicated malaria.
Adjei, GO; Alifrangis, M; Goka, BQ; Hoegberg, LC; Kristensen, K; Kurtzhals, JA; Rodrigues, OP, 2008
)
0.35
" A new dosage form consisting of a fixed-dose combination of AS and AQ was found to have no effect on the pharmacokinetic parameters of AQ and DAQ."( Population pharmacokinetics and pharmacodynamic considerations of amodiaquine and desethylamodiaquine in Kenyan adults with uncomplicated malaria receiving artesunate-amodiaquine combination therapy.
Carn, G; Jullien, V; Juma, E; Kiechel, JR; Obonyo, C; Ogutu, B, 2010
)
0.59
"Maximum concentrations of AQ increased by 12% with the concurrent dosing of MD and by 85% in the group of mice pre-treated with MD."( Influence of MAMA decoction, an Herbal Antimalarial, on the Pharmacokinetics of Amodiaquine in Mice.
Adeagbo, BA; Adehin, A; Adepiti, AO; Bolaji, OO; Elujoba, AA, 2020
)
0.56
" We also measured the spontaneous beating heart rate after cumulative dosing of amodiaquine and desethylamodiaquine in isolated mouse atrial preparations."( Cardiovascular concentration-effect relationships of amodiaquine and its metabolite desethylamodiaquine: Clinical and preclinical studies.
Burton, RB; Capel, RA; Chan, XHS; Chotsiri, P; Cremer, MA; Hanafiah, M; Hanboonkunupakarn, B; Kiechel, JR; Lee, SJ; Ogutu, B; Pike, J; Tarning, J; Taylor, WRJ; White, NJ; Win, YN, 2023
)
1.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (7)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 1A2Homo sapiens (human)IC50 (µMol)28.00000.00011.774010.0000AID346854; AID419167
Cytochrome P450 3A4Homo sapiens (human)IC50 (µMol)62.00000.00011.753610.0000AID346855; AID346856; AID419164; AID419165
Cytochrome P450 2C8Homo sapiens (human)IC50 (µMol)20.00000.00081.88487.9000AID346852; AID419169
Cytochrome P450 2D6Homo sapiens (human)IC50 (µMol)6.40000.00002.015110.0000AID346850; AID419168
Cytochrome P450 2C9 Homo sapiens (human)IC50 (µMol)58.00000.00002.800510.0000AID346853; AID419170
Cytochrome P450 2C19Homo sapiens (human)IC50 (µMol)54.00000.00002.398310.0000AID346851; AID419171
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC50 (µMol)9.50000.00091.901410.0000AID346849
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (65)

Processvia Protein(s)Taxonomy
steroid catabolic processCytochrome P450 1A2Homo sapiens (human)
porphyrin-containing compound metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1A2Homo sapiens (human)
cholesterol metabolic processCytochrome P450 1A2Homo sapiens (human)
estrogen metabolic processCytochrome P450 1A2Homo sapiens (human)
toxin biosynthetic processCytochrome P450 1A2Homo sapiens (human)
post-embryonic developmentCytochrome P450 1A2Homo sapiens (human)
alkaloid metabolic processCytochrome P450 1A2Homo sapiens (human)
regulation of gene expressionCytochrome P450 1A2Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 1A2Homo sapiens (human)
dibenzo-p-dioxin metabolic processCytochrome P450 1A2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
lung developmentCytochrome P450 1A2Homo sapiens (human)
methylationCytochrome P450 1A2Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 1A2Homo sapiens (human)
retinol metabolic processCytochrome P450 1A2Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 1A2Homo sapiens (human)
cellular respirationCytochrome P450 1A2Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 1A2Homo sapiens (human)
hydrogen peroxide biosynthetic processCytochrome P450 1A2Homo sapiens (human)
oxidative demethylationCytochrome P450 1A2Homo sapiens (human)
cellular response to cadmium ionCytochrome P450 1A2Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
lipid hydroxylationCytochrome P450 2C8Homo sapiens (human)
organic acid metabolic processCytochrome P450 2C8Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C8Homo sapiens (human)
steroid metabolic processCytochrome P450 2C8Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C8Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C8Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C8Homo sapiens (human)
retinol metabolic processCytochrome P450 2C8Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 2C8Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C8Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C8Homo sapiens (human)
oxidative demethylationCytochrome P450 2C8Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C8Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2D6Homo sapiens (human)
steroid metabolic processCytochrome P450 2D6Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2D6Homo sapiens (human)
estrogen metabolic processCytochrome P450 2D6Homo sapiens (human)
coumarin metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid catabolic processCytochrome P450 2D6Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2D6Homo sapiens (human)
isoquinoline alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2D6Homo sapiens (human)
retinol metabolic processCytochrome P450 2D6Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2D6Homo sapiens (human)
negative regulation of bindingCytochrome P450 2D6Homo sapiens (human)
oxidative demethylationCytochrome P450 2D6Homo sapiens (human)
negative regulation of cellular organofluorine metabolic processCytochrome P450 2D6Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C9 Homo sapiens (human)
steroid metabolic processCytochrome P450 2C9 Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2C9 Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C9 Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C9 Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
urea metabolic processCytochrome P450 2C9 Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 2C9 Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C9 Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
amide metabolic processCytochrome P450 2C9 Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
oxidative demethylationCytochrome P450 2C9 Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
long-chain fatty acid metabolic processCytochrome P450 2C19Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C19Homo sapiens (human)
steroid metabolic processCytochrome P450 2C19Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C19Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C19Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by hormonePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane depolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (45)

Processvia Protein(s)Taxonomy
monooxygenase activityCytochrome P450 1A2Homo sapiens (human)
iron ion bindingCytochrome P450 1A2Homo sapiens (human)
protein bindingCytochrome P450 1A2Homo sapiens (human)
electron transfer activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 1A2Homo sapiens (human)
enzyme bindingCytochrome P450 1A2Homo sapiens (human)
heme bindingCytochrome P450 1A2Homo sapiens (human)
demethylase activityCytochrome P450 1A2Homo sapiens (human)
caffeine oxidase activityCytochrome P450 1A2Homo sapiens (human)
aromatase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1A2Homo sapiens (human)
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
monooxygenase activityCytochrome P450 2C8Homo sapiens (human)
iron ion bindingCytochrome P450 2C8Homo sapiens (human)
protein bindingCytochrome P450 2C8Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C8Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 2C8Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C8Homo sapiens (human)
aromatase activityCytochrome P450 2C8Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 2C8Homo sapiens (human)
heme bindingCytochrome P450 2C8Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C8Homo sapiens (human)
monooxygenase activityCytochrome P450 2D6Homo sapiens (human)
iron ion bindingCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activityCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2D6Homo sapiens (human)
heme bindingCytochrome P450 2D6Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
iron ion bindingCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C9 Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
aromatase activityCytochrome P450 2C9 Homo sapiens (human)
heme bindingCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C9 Homo sapiens (human)
monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
iron ion bindingCytochrome P450 2C19Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxygen bindingCytochrome P450 2C19Homo sapiens (human)
enzyme bindingCytochrome P450 2C19Homo sapiens (human)
heme bindingCytochrome P450 2C19Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
aromatase activityCytochrome P450 2C19Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C19Homo sapiens (human)
transcription cis-regulatory region bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ubiquitin protein ligase bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
identical protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein homodimerization activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C3HC4-type RING finger domain bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (10)

Processvia Protein(s)Taxonomy
endoplasmic reticulum membraneCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C8Homo sapiens (human)
plasma membraneCytochrome P450 2C8Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C8Homo sapiens (human)
cytoplasmCytochrome P450 2C8Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C8Homo sapiens (human)
mitochondrionCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulumCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2D6Homo sapiens (human)
cytoplasmCytochrome P450 2D6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C9 Homo sapiens (human)
plasma membraneCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
cytoplasmCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C19Homo sapiens (human)
plasma membraneCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
cytoplasmCytochrome P450 2C19Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (104)

Assay IDTitleYearJournalArticle
AID558834Antimalarial activity against Plasmodium falciparum IMT Bres assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID419159Metabolic stability in mouse liver microsomes assessed as intrinsic clearance per gram of liver2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4'-fluoro and 4'-chloro analogues of amodiaquine. Identification of a suitable "back-up" compound for N-tert-butyl isoquine.
AID511253Antimicrobial activity against chloroquine-sensitive Plasmodium falciparum D6 by ELISA2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda.
AID477939Antiplasmodial activity against chloroquine-susceptible Plasmodium falciparum 8425 infected in human erythrocytes assessed as inhibition of [3H]hypoxanthine uptake after 48 hrs2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
Antimalarial versus cytotoxic properties of dual drugs derived from 4-aminoquinolines and Mannich bases: interaction with DNA.
AID564297Antimalarial activity against Plasmodium falciparum IMT 9881 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID563688Antimalarial activity against Plasmodium falciparum assessed as resistant isolates2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Plasmodium falciparum drug resistance in Madagascar: facing the spread of unusual pfdhfr and pfmdr-1 haplotypes and the decrease of dihydroartemisinin susceptibility.
AID346880Protein binding in human2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century.
AID419171Inhibition of human CYP2C192009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4'-fluoro and 4'-chloro analogues of amodiaquine. Identification of a suitable "back-up" compound for N-tert-butyl isoquine.
AID558836Antimalarial activity against Plasmodium falciparum IMT A4 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID558844Antimalarial activity against Plasmodium falciparum IMT K2 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID564300Antimalarial activity against Plasmodium falciparum IMT 10500 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID1812460Antiplasmodial activity against Cambodian multidrug-resistant Plasmodium falciparum isolate incubated for 96 hrs measured by SYBR Green 1 assay2021Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14
Procainamide-SAHA Fused Inhibitors of hHDAC6 Tackle Multidrug-Resistant Malaria Parasites.
AID564305Antimalarial activity against Plasmodium falciparum IMT L1 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID564286Antimalarial activity against Plasmodium falciparum D6 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID477945Antiplasmodial activity against chloroquine-susceptible Plasmodium falciparum W2 infected in human erythrocytes assessed as inhibition of [3H]hypoxanthine uptake after 48 hrs2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
Antimalarial versus cytotoxic properties of dual drugs derived from 4-aminoquinolines and Mannich bases: interaction with DNA.
AID558826Antimalarial activity against Plasmodium falciparum 3D7 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID563687Antimalarial activity against Plasmodium falciparum assessed as parasite growth inhibition after 48 hrs by [3H]hypoxanthin incorporation assay2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Plasmodium falciparum drug resistance in Madagascar: facing the spread of unusual pfdhfr and pfmdr-1 haplotypes and the decrease of dihydroartemisinin susceptibility.
AID558831Antimalarial activity against Plasmodium falciparum PA assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID558829Antimalarial activity against Plasmodium falciparum FCM29 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID419165Inhibition of human CYP3A4 using PPR substrate2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4'-fluoro and 4'-chloro analogues of amodiaquine. Identification of a suitable "back-up" compound for N-tert-butyl isoquine.
AID558841Antimalarial activity against Plasmodium falciparum IMT 10500 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID477947Antiplasmodial activity against chloroquine-susceptible Plasmodium falciparum K14 infected in human erythrocytes assessed as inhibition of [3H]hypoxanthine uptake after 48 hrs2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
Antimalarial versus cytotoxic properties of dual drugs derived from 4-aminoquinolines and Mannich bases: interaction with DNA.
AID562110Antiplasmodial activity against multidrug-resistant Plasmodium falciparum VS/1 by [3H]hypoxanthine incorporation assay2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
In vitro chemosensitization of Plasmodium falciparum to antimalarials by verapamil and probenecid.
AID419168Inhibition of human CYP2D62009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4'-fluoro and 4'-chloro analogues of amodiaquine. Identification of a suitable "back-up" compound for N-tert-butyl isoquine.
AID477948Antiplasmodial activity against chloroquine-susceptible Plasmodium falciparum FCM29 infected in human erythrocytes assessed as inhibition of [3H]hypoxanthine uptake after 48 hrs2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
Antimalarial versus cytotoxic properties of dual drugs derived from 4-aminoquinolines and Mannich bases: interaction with DNA.
AID558835Antimalarial activity against Plasmodium falciparum IMT Guy assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID346874Antimalarial activity as reduced parasitaemia at day 4 against Plasmodium yoelii 17X infected CD1 mice (Mus musculus) at 40 mg/kg2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century.
AID477944Antiplasmodial activity against chloroquine-susceptible Plasmodium falciparum FCR3 infected in human erythrocytes assessed as inhibition of [3H]hypoxanthine uptake after 48 hrs2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
Antimalarial versus cytotoxic properties of dual drugs derived from 4-aminoquinolines and Mannich bases: interaction with DNA.
AID564304Antimalarial activity against Plasmodium falciparum IMT K4 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID477943Antiplasmodial activity against chloroquine-susceptible Plasmodium falciparum Bres infected in human erythrocytes assessed as inhibition of [3H]hypoxanthine uptake after 48 hrs2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
Antimalarial versus cytotoxic properties of dual drugs derived from 4-aminoquinolines and Mannich bases: interaction with DNA.
AID558845Antimalarial activity against Plasmodium falciparum IMT K4 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID564299Antimalarial activity against Plasmodium falciparum IMT 10354 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID564285Antimalarial activity against Plasmodium falciparum W2 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID346852Inhibition of human recombinant CYP2C82009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century.
AID419162Metabolic stability in monkey liver microsomes assessed as intrinsic clearance per gram of liver2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4'-fluoro and 4'-chloro analogues of amodiaquine. Identification of a suitable "back-up" compound for N-tert-butyl isoquine.
AID346854Inhibition of human recombinant CYP1A22009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century.
AID419169Inhibition of human CYP2C82009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4'-fluoro and 4'-chloro analogues of amodiaquine. Identification of a suitable "back-up" compound for N-tert-butyl isoquine.
AID564306Antimalarial activity against Plasmodium falciparum IMT Vol assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID564295Antimalarial activity against Plasmodium falciparum IMT 31 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID564288Antimalarial activity against Plasmodium falciparum FCR3 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID564292Antimalarial activity against Plasmodium falciparum IMT Bres assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID477942Antiplasmodial activity against chloroquine-susceptible Plasmodium falciparum PA infected in human erythrocytes assessed as inhibition of [3H]hypoxanthine uptake after 48 hrs2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
Antimalarial versus cytotoxic properties of dual drugs derived from 4-aminoquinolines and Mannich bases: interaction with DNA.
AID511252Antimicrobial activity against chloroquine-sensitive Plasmodium falciparum W2 by ELISA2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda.
AID553831Plasma concentration in children with uncomplicated malaria assessed as desethylamodiaquine at 10 mg/kg, po administered as single dose measured on day 32008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Effect of concomitant artesunate administration and cytochrome P4502C8 polymorphisms on the pharmacokinetics of amodiaquine in Ghanaian children with uncomplicated malaria.
AID558843Antimalarial activity against Plasmodium falciparum IMT K14 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID511256Antimicrobial activity against Plasmodium falciparum harboring mdr1 N86Y/D1246Y/Y184F mutant gene by ELISA2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda.
AID553838Toxicity in children with uncomplicated malaria assessed as elevated serum aminotransferase levels at 10 mg/kg, po administered as single dose2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Effect of concomitant artesunate administration and cytochrome P4502C8 polymorphisms on the pharmacokinetics of amodiaquine in Ghanaian children with uncomplicated malaria.
AID477937Antiplasmodial activity against chloroquine-susceptible Plasmodium falciparum 3D7 infected in human erythrocytes assessed as inhibition of [3H]hypoxanthine uptake after 48 hrs2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
Antimalarial versus cytotoxic properties of dual drugs derived from 4-aminoquinolines and Mannich bases: interaction with DNA.
AID564298Antimalarial activity against Plasmodium falciparum IMT 10336 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID346850Inhibition of human recombinant CYP2D62009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century.
AID419170Inhibition of human CYP2C92009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4'-fluoro and 4'-chloro analogues of amodiaquine. Identification of a suitable "back-up" compound for N-tert-butyl isoquine.
AID564303Antimalarial activity against Plasmodium falciparum IMT K2 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID564284Antimalarial activity against Plasmodium falciparum 3D7 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID558842Antimalarial activity against Plasmodium falciparum IMT 16332 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID564290Antimalarial activity against Plasmodium falciparum HB3 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID558832Antimalarial activity against Plasmodium falciparum HB3 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID419161Metabolic stability in dog liver microsomes assessed as intrinsic clearance per gram of liver2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4'-fluoro and 4'-chloro analogues of amodiaquine. Identification of a suitable "back-up" compound for N-tert-butyl isoquine.
AID564294Antimalarial activity against Plasmodium falciparum IMT A4 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID564293Antimalarial activity against Plasmodium falciparum IMT Guy assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID346855Inhibition of human recombinant CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin as substrate2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century.
AID158707In vitro inhibition of chloroquine-sensitive Plasmodium falciparum HB31997Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4
Synthesis, antimalarial activity, and molecular modeling of tebuquine analogues.
AID1060786Antiplasmodial activity against chloroquine-resistant ring stage Plasmodium falciparum W2 assessed as parasitemia after 48 hrs by flow cytometry2014European journal of medicinal chemistry, Jan, Volume: 71Urea/oxalamide tethered β-lactam-7-chloroquinoline conjugates: synthesis and in vitro antimalarial evaluation.
AID553841Toxicity in children with uncomplicated malaria assessed as excessive sleepiness at 10 mg/kg, po administered as single dose2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Effect of concomitant artesunate administration and cytochrome P4502C8 polymorphisms on the pharmacokinetics of amodiaquine in Ghanaian children with uncomplicated malaria.
AID477940Antiplasmodial activity against chloroquine-susceptible Plasmodium falciparum Voll infected in human erythrocytes assessed as inhibition of [3H]hypoxanthine uptake after 48 hrs2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
Antimalarial versus cytotoxic properties of dual drugs derived from 4-aminoquinolines and Mannich bases: interaction with DNA.
AID228277Cellular accumulation ratio (CAR) for chloroquine sensitive HB3 strain of Plasmodium falciparum1997Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4
Synthesis, antimalarial activity, and molecular modeling of tebuquine analogues.
AID558830Antimalarial activity against Plasmodium falciparum FCR3 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID564301Antimalarial activity against Plasmodium falciparum IMT 16332 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID419164Inhibition of human CYP3A4 using DEF substrate2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4'-fluoro and 4'-chloro analogues of amodiaquine. Identification of a suitable "back-up" compound for N-tert-butyl isoquine.
AID346853Inhibition of human recombinant CYP2C92009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century.
AID477941Antiplasmodial activity against chloroquine-susceptible Plasmodium falciparum L1 infected in human erythrocytes assessed as inhibition of [3H]hypoxanthine uptake after 48 hrs2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
Antimalarial versus cytotoxic properties of dual drugs derived from 4-aminoquinolines and Mannich bases: interaction with DNA.
AID558828Antimalarial activity against Plasmodium falciparum D6 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID1899027Antiplasmodial activity against CQ-susceptible Plasmodium falciparum 3D7 infected in human erythrocytes assessed as inhibition of parasite growth measured after 72 hrs by HRP2-ELISA2022European journal of medicinal chemistry, Jan-15, Volume: 228Design, synthesis, and characterization of novel aminoalcohol quinolines with strong in vitro antimalarial activity.
AID558840Antimalarial activity against Plasmodium falciparum IMT 10336 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID419163Metabolic stability in human liver microsomes assessed as intrinsic clearance per gram of liver2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4'-fluoro and 4'-chloro analogues of amodiaquine. Identification of a suitable "back-up" compound for N-tert-butyl isoquine.
AID553837Toxicity in children with uncomplicated malaria assessed as neutropenia at at 10 mg/kg, po administered as single dose2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Effect of concomitant artesunate administration and cytochrome P4502C8 polymorphisms on the pharmacokinetics of amodiaquine in Ghanaian children with uncomplicated malaria.
AID511251Antimicrobial activity against Plasmodium falciparum by ELISA2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda.
AID477938Antiplasmodial activity against chloroquine-susceptible Plasmodium falciparum D6 infected in human erythrocytes assessed as inhibition of [3H]hypoxanthine uptake after 48 hrs2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
Antimalarial versus cytotoxic properties of dual drugs derived from 4-aminoquinolines and Mannich bases: interaction with DNA.
AID419160Metabolic stability in rat liver microsomes assessed as intrinsic clearance per gram of liver2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4'-fluoro and 4'-chloro analogues of amodiaquine. Identification of a suitable "back-up" compound for N-tert-butyl isoquine.
AID564296Antimalarial activity against Plasmodium falciparum IMT 8425 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID564287Antimalarial activity against Plasmodium falciparum FCM29 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID346865Protein binding in mouse2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century.
AID553840Toxicity in children with uncomplicated malaria assessed as pruritus at 10 mg/kg, po administered as single dose2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Effect of concomitant artesunate administration and cytochrome P4502C8 polymorphisms on the pharmacokinetics of amodiaquine in Ghanaian children with uncomplicated malaria.
AID558839Antimalarial activity against Plasmodium falciparum IMT 9881 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID529905Antiplasmodial activity against Plasmodium falciparum harboring K1 allele group of msp1, 3D7 allele group of msp2 gene and 94 bp of 7A11, 196bp of C4M79 and 336bp of C4M69 locus measured on day 23 by [3H]hypoxanthine incorporation assay2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
First case of emergence of atovaquone-proguanil resistance in Plasmodium falciparum during treatment in a traveler in Comoros.
AID346856Inhibition of human recombinant CYP3A4 using N-N,diethyl-formamide as substrate2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century.
AID558846Antimalarial activity against Plasmodium falciparum IMT L1 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID564302Antimalarial activity against Plasmodium falciparum IMT K14 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID558833Antimalarial activity against Plasmodium falciparum 106/1 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID419167Inhibition of human CYP1A22009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4'-fluoro and 4'-chloro analogues of amodiaquine. Identification of a suitable "back-up" compound for N-tert-butyl isoquine.
AID558827Antimalarial activity against Plasmodium falciparum W2 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID1899029Selectivity index, ratio of IC50 for antiplasmodial activity against CQ-susceptible Plasmodium falciparum 3D7 to IC50 for antiplasmodial activity CQ-resistant Plasmodium falciparum W2 by HRP2-ELISA2022European journal of medicinal chemistry, Jan-15, Volume: 228Design, synthesis, and characterization of novel aminoalcohol quinolines with strong in vitro antimalarial activity.
AID564289Antimalarial activity against Plasmodium falciparum PA assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID558838Antimalarial activity against Plasmodium falciparum IMT 8425 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID564291Antimalarial activity against Plasmodium falciparum 106/1 assessed as inhibition of [3H] incorporation after 48 hrs by scintillation counter2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.
AID1899028Antiplasmodial activity CQ-resistant Plasmodium falciparum W2 infected in human erythrocytes assessed as inhibition of parasite growth measured after 72 hrs by HRP2-ELISA2022European journal of medicinal chemistry, Jan-15, Volume: 228Design, synthesis, and characterization of novel aminoalcohol quinolines with strong in vitro antimalarial activity.
AID477946Antiplasmodial activity against chloroquine-susceptible Plasmodium falciparum K2 infected in human erythrocytes assessed as inhibition of [3H]hypoxanthine uptake after 48 hrs2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
Antimalarial versus cytotoxic properties of dual drugs derived from 4-aminoquinolines and Mannich bases: interaction with DNA.
AID346851Inhibition of human recombinant CYP2C192009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century.
AID553839Toxicity in children with uncomplicated malaria assessed as bradycardia at 10 mg/kg, po administered as single dose2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Effect of concomitant artesunate administration and cytochrome P4502C8 polymorphisms on the pharmacokinetics of amodiaquine in Ghanaian children with uncomplicated malaria.
AID511255Antimicrobial activity against chloroquine-resistant Plasmodium falciparum K1 by ELISA2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda.
AID511254Antimicrobial activity against chloroquine-resistant Plasmodium falciparum HB3 by ELISA2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda.
AID346849Inhibition of human cloned ERG2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century.
AID558847Antimalarial activity against Plasmodium falciparum IMT Vol assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID558837Antimalarial activity against Plasmodium falciparum IMT 31 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (93)

TimeframeStudies, This Drug (%)All Drugs %
pre-19908 (8.60)18.7374
1990's10 (10.75)18.2507
2000's31 (33.33)29.6817
2010's35 (37.63)24.3611
2020's9 (9.68)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.82

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.82 (24.57)
Research Supply Index4.71 (2.92)
Research Growth Index4.90 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.82)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials14 (14.58%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (1.04%)4.05%
Observational0 (0.00%)0.25%
Other81 (84.38%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]